In BC, a high number of primary tumor-infiltrating lymphocytes (TILs) have been related to better response to neoadjuvant therapy in all BC subtypes and to a better prognosis in triple negative breast cancer (TNBC) and HER2 positive BC patients (7, 8). Here, ERBB2 is linked to neoplasm.